{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+1b&page=27", "query": { "intervention": "Phase 1b", "page": 27 }, "page_size": 10 }, "pagination": { "page": 27, "page_size": 10, "total_count": 2481, "total_pages": 249, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+1b&page=28&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+1b&page=26&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T12:47:57.329Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01084252", "title": "Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematological Malignancy" ], "interventions": [ { "name": "Isatuximab SAR650984", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 351, "start_date": "2010-05-11", "completion_date": "2023-07-13", "has_results": true, "last_update_posted_date": "2024-11-01", "last_synced_at": "2026-10-20T12:47:57.329Z", "location_count": 16, "location_summary": "Scottsdale, Arizona • San Francisco, California • Atlanta, Georgia + 13 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01084252" }, { "nct_id": "NCT05121038", "title": "CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colon Cancer", "Pancreas Cancer", "Digestive Cancer" ], "interventions": [ { "name": "CEND-1", "type": "DRUG" }, { "name": "Panitumumab", "type": "DRUG" }, { "name": "Folfirinox", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Anup Kasi", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2021-10-20", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2024-12-17", "last_synced_at": "2026-10-20T12:47:57.329Z", "location_count": 3, "location_summary": "Fairway, Kansas • Kansas City, Kansas • North Kansas City, Missouri", "locations": [ { "city": "Fairway", "state": "Kansas" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "North Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05121038" }, { "nct_id": "NCT01580969", "title": "Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Glioma" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Minocycline", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2012-07-06", "completion_date": "2018-05-15", "has_results": true, "last_update_posted_date": "2019-08-16", "last_synced_at": "2026-10-20T12:47:57.329Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01580969" }, { "nct_id": "NCT04570631", "title": "Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Eftozanermin alfa", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2020-11-05", "completion_date": "2025-05-05", "has_results": false, "last_update_posted_date": "2025-05-16", "last_synced_at": "2026-10-20T12:47:57.329Z", "location_count": 5, "location_summary": "Atlanta, Georgia • Louisville, Kentucky • Boston, Massachusetts + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04570631" }, { "nct_id": "NCT05963997", "title": "A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Breast Cancer", "Locally Advanced Breast Cancer", "Breast Cancer" ], "interventions": [ { "name": "Samuraciclib", "type": "DRUG" }, { "name": "Elacestrant Dihydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Carrick Therapeutics Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2023-10-09", "completion_date": "2026-03-06", "has_results": false, "last_update_posted_date": "2026-03-23", "last_synced_at": "2026-10-20T12:47:57.329Z", "location_count": 5, "location_summary": "Chicago, Illinois • Boston, Massachusetts • Cleveland, Ohio + 2 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05963997" }, { "nct_id": "NCT02323113", "title": "Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myelogenous Leukemia" ], "interventions": [ { "name": "TAK-659", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calithera Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2015-03-09", "completion_date": "2018-08-15", "has_results": true, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-10-20T12:47:57.329Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Chicago, Illinois • Niles, Illinois + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Niles", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02323113" }, { "nct_id": "NCT02334462", "title": "Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel , a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria, in Adults in the U.S. and Mali", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malaria" ], "interventions": [ { "name": "Pfs230D1M-EPA/Alhydrogel", "type": "BIOLOGICAL" }, { "name": "Pfs25M-EPA/Alhydrogel", "type": "BIOLOGICAL" }, { "name": "TWINRIX", "type": "DRUG" }, { "name": "Menactra", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 538, "start_date": "2015-01-07", "completion_date": "2018-10-22", "has_results": false, "last_update_posted_date": "2019-04-11", "last_synced_at": "2026-10-20T12:47:57.329Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02334462" }, { "nct_id": "NCT04047862", "title": "Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced and Metastatic Solid Tumors" ], "interventions": [ { "name": "Ociperlimab", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "5fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 446, "start_date": "2019-08-15", "completion_date": "2024-08-07", "has_results": true, "last_update_posted_date": "2025-08-22", "last_synced_at": "2026-10-20T12:47:57.329Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Fort Myers, Florida • Jacksonville, Florida + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04047862" }, { "nct_id": "NCT06056310", "title": "Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Xevinapant", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "intensity-modulated radiation therapy (IMRT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2024-01-18", "completion_date": "2024-08-20", "has_results": true, "last_update_posted_date": "2025-09-29", "last_synced_at": "2026-10-20T12:47:57.329Z", "location_count": 5, "location_summary": "Miami Beach, Florida • Detroit, Michigan • The Bronx, New York + 2 more", "locations": [ { "city": "Miami Beach", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "The Bronx", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06056310" }, { "nct_id": "NCT02959918", "title": "Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gout Chronic", "Hyperuricemia" ], "interventions": [ { "name": "SEL-212", "type": "DRUG" }, { "name": "SEL-037", "type": "DRUG" }, { "name": "SVP-rapamycin (SEL-110)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Selecta Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "21 Years to 75 Years" }, "enrollment_count": 152, "start_date": "2016-10", "completion_date": "2019-01", "has_results": true, "last_update_posted_date": "2022-02-14", "last_synced_at": "2026-10-20T12:47:57.329Z", "location_count": 13, "location_summary": "Anaheim, California • El Cajon, California • Irvine, California + 10 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "El Cajon", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Clearwater", "state": "Florida" }, { "city": "DeBary", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02959918" } ] }